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Substantial evidence exists to suggest lyssaviruses evolved in
Chiropteran (bat) hosts. Infection by each Lyssavirus (Family
Rhabdoviridae) causes rabies encephalomyelitis and cases are indis-
tinguishable by clinical presentation, regardless of which speciesinfects the individual. All Lyssavirus species, other than Mokola virus
(MOKV), are distributed in New or OldWorld bats (Fooks, 2004), with
rabies virus (RABV) routinely isolated from New World bats.
Lyssavirus species isolated from Old World bats include Lagos bat
virus (LBV), Duvenhage virus (DUVV), European bat lyssavirus type 1
(EBLV 1) and 2 (EBLV 2), Australian bat virus (ABLV), Irkut virus
(IRKV), Khujand virus (KHUV) andWest Caucasian bat virus (WCBV).
MOKV has been isolated from terrestrial mammals only, although
surveillance has been limited (Nel et al., 2000). Recently, a putative
new species, Shimoni bat virus (SHIBV), was isolated from a Kenyan
bat in 2009 (Kuzmin et al., 2010).
There are approximately 1100 species of bats, comprising over 20%
of extant mammalian species, which live on every continent other than
Antarctica (Teeling et al., 2005). It has become clear that designated
“rabies free” nations, such as the UK and Australia, have endemic
lyssaviruses circulating within bat populations (Banyard et al., 2010;
Warrilow, 2005). In both nations humans have died from lyssavirus
infection transmitted by bats (Fooks et al., 2003; Fraser et al., 1996). The
geographic distribution of bats together with the apparent ubiquitous
Table 1
Characteristics of Eidolon helvum caught for this study.
Sex Age Location
Accra Kumasi Tanoboasea
Female SI 5 4 17
SM 1 2 6
Male SI 23 4 17
SM 64 24 16
Total 93 34 56
a In addition, a H. monstrosus bat was caught at this location. SI—sexually immature.
SM—sexually mature.
184 E. Wright et al. / Virology 408 (2010) 183–189infection of bat populations with lyssaviruses means that, with the
exception of Antarctica and some oceanic islands, new lyssavirusesmay
spill-over from these reservoir populations into new potential reser-
voirs, such as dogs, or to dead-end hosts, such as humans, anywhere on
the globe. The true threat to the human and animal populations posed
by the spill-over of these viruses is unknown due to the lack of
knowledge at both the epidemiological and molecular level (Fooks,
2004). While reported human infections by lyssaviruses other than
RABV are rare (Johnson et al., 2010), they are fatal and the real number
of cases is unknown due to limited surveillance and misdiagnosis
(Mallewa et al., 2007; Nel and Rupprecht, 2007).
Each Lyssavirus species belongs to one of two phylogroups based on
their cross neutralisation proﬁle, pathogenicity and genetic relatedness
(Badrane et al., 2001; Kuzmin et al., 2009). LBV and MOKV belong to
phylogroup2,with theothers comprisingphylogroup1, apart fromSHIBV
andWCBV, which are awaiting ofﬁcial classiﬁcation but have tentatively
been placed in phylogroup 2 and a putative phylogroup 3, respectively.
TheWorldHealthOrganisation estimates 55,000humandeaths eachyear
from rabies (World-Health-Organisation, 2008), primarily due to RABV
circulating globally in domestic dogs and wild carnivores (such as foxes,
skunks and racoons). Potential epidemicsof viruses againstwhich current
biologicals offer no protection (LBV, MOKV, WCBV and possibly SHIBV
(Hanlon et al., 2005; Kuzmin et al., 2010)) can only be determined if the
infectiondynamics of these viruses are understoodwithin reservoir hosts.
The absence of a knownMOKV reservoir, for example, is a substantial gap
in the understanding of Lyssavirus ecology and evolution.While there is a
suggestion that shrews (family Soricidae) are reservoirs, the number of
isolations from shrews is currently limited to ﬁve (Sabeta et al., 2007),
with three isolated in a single study (Shope et al., 1970).
Four recognised Lyssavirus species (RABV, MOKV, DUVV, and LBV)
and SHIBV have been isolated from African mammals (King et al., 1993,
1994;Kuzminet al., 2010, 2008a; Sabeta et al., 2003, 2007; vanThiel et al.,
2008). LBV reportedly contains at least two clades that are divergent
enough to suggest they may represent different species (Delmas et al.,
2008; Markotter et al., 2008). RABV andMOKV have never been isolated
from bats in Africa, while LBV, DUVV and SHIBV have, with both LBV and
DUVV occasionally isolated from other mammals (Kuzmin et al., 2010,
2008a; Sabeta et al., 2007; van Thiel et al., 2008). Africa therefore
possesses the greatest known Lyssavirus diversity, both genetically and
serologically. Given that such diversity exists in Africa, it has been
hypothesised that early evolution and divergence of lyssaviruses
occurred in African bats (Nel and Rupprecht, 2007). Recently, surveil-
lance programs and greater access to serosurveillance techniques have
resulted in thediscoveryof ahigh seroprevalenceagainst LBV inWest (3–
37%) and East (29–67%) African fruit bats (Dzikwi et al., 2010; Hayman
et al., 2008a;Kuzmin et al., 2008a).WCBVhas not been isolated frombats
in Africa, the only isolation of WCBV was from Miniopterus bats in the
West Caucasus (Botvinkin et al., 2003), however a high seroprevalence of
anti-WCBV antibodies was detected in African Miniopterus when the
appropriate study was undertaken (Kuzmin et al., 2008b). These reports
and others (Cleaveland, 1998; Knobel et al., 2005) highlight the limited
understanding of lyssavirus epidemiology.
Recently, Streicker et al. (2010) suggested that the phylogenic
distance between bat species is an important factor in cross-species
transmission and host shifts of rabies viruses in North America.
Coupled with the probable co-evolution of lyssaviruses and bats it is
possible that the species speciﬁcity shown for those lyssaviruses
isolated in Eurasia, WCBV and European bat lyssaviruses 1 and 2, in
epidemiological studies to-date could be caused by an intrinsic innate
restriction factor(s) similar to those reported for retroviruses (Neil
and Bieniasz, 2009). However, given LBV has been isolated from ﬁve
different species of frugivorous and insectivorous bats, other
behavioural, ecological or cell entry restrictions could also be
important factors in determining lyssaviruses susceptibility.
Given that bats can be extraordinarily small, with many common
species weighing less than 5 g, handling animals and, in particular,bleeding live animals to obtain adequate volumes of sera is particularly
difﬁcult. Indeed, several seroprevalence studies report pooling sera as a
necessarymethod to enable serological tests to be undertaken, such as a
study of EBLV-2 in Scotland (Brookes et al., 2005). Current studies of bat
lyssavirus ecology and evolution in Africa are hampered by resource-
limited laboratories and the requirement for large volumes of sera for
routine virus neutralising antibody (VNAb) tests. In this study we
adapted a lyssavirus pseudotype neutralisation assay (PNA; Wright
et al., 2009, 2008) to a multiplex format allowing in-depth serosurveil-
lance to be undertaken. Spill-over of phylogroup two lyssaviruses has
the potential to cause fatal zoonotic transmission events to dead-end
hosts, such ashumans, or emergence in terrestrial carnivores. Due to the
limited data available it is unknownwhether these viruses are endemic
within bat populations or whether there is any species speciﬁcity. In
order to address this we undertook investigations to determine if the
previously reported high seroprevalence of anti-LBV antibodies in
Ghanaian fruit bats (Eidolon helvum [E. helvum]) was due to a recent
epidemic within the colony or due to endemic infection. In addition, we
tested the hypothesis that lyssavirus circulation is species speciﬁc so
undertook seroprevalence studies of LBV, MOKV (phylogroup 2) and
WCBV (putative phylogroup 3) in a potential reservoir, E. helvum, using
a novel multiplexed PNA assay.
Results
Characteristics of bats sampled for study
Details of the bats sampled are provided in Table 1. Brieﬂy, batswere
caught in three roosting colony sites in urban (Accra and Kumasi) or
rural (Tanoboase) Ghana (Fig. 1A), 184 serum samples were collected
by manually restraining the animals (Fig. 1B). Classiﬁcation, using a
dichotomous key as previously described (Hayman et al., 2008a),
revealed 183 were from E. helvum and a single sample was from a
sexually mature male Hypsignathus monstrosus caught in Tanoboase.
Eighty-one percent of the E. helvum sampled for this study were males
and the majority of bats, 62%, were sexually mature males or females.
Strongly correlated titres between mFAVN and standard and multiplex
pseudotype neutralisation assays for LBV and MOKV serology
We undertook a deﬁnitive study comparing titres achieved in LBV
PNA and modiﬁed ﬂuorescent antibody virus neutralisation assays
(mFAVN) for 184 bat serum samples. Analysis of the VNAb titres
obtained for each serum sample using the PNA or mFAVN reveals a
correlation of 0.83 (pb0.0001; Pearson's product-moment correla-
tion; Fig. 2A). As no serum sample neutralised ptRABV challenge virus
standard 11 (CVS-11) above a dilution of 1:20 (data not shown), any
sample that scored N1:40 was classiﬁed as VNAb positive. Using these
parameters, both the sensitivity and speciﬁcity of the PNA were high,
95% and 93% respectively, with nine serum samples classiﬁed as
negative by the PNA but positive by the mFAVN and 12 positive in the
PNA but negative by mFAVN (Fig. 2A). It should be noted that
discordant results for both assays occur only at low VNAb titres.
Fig. 1. Amap of Ghana showing the three Eidolon helvum colonies fromwhich bats were
sampled, indicated by black stars (A). Bats were caught in mist nets with blood samples
taken from the propatagial vein (B).
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multiplex platformwas incorporated into the PNA. Thismade it possible
to measure VNAb titres against two different lyssaviruses in the same
well using an equal volume of sera as the standard PNA. A pilot
experiment was undertaken with 21 bat serum samples using ptLBV
carrying the renilla luciferase gene and ptMOKV encoding the ﬁreﬂy
luciferase gene. Standard and dual PNAs were undertaken for each
sample. Analysis of VNAb titres obtained with each assay reveals a
strong correlation between the results of the standard and dual PNAs
(0.97; pb0.0001; Pearson's product-moment correlation; Fig. 2B). A
strong correlation was also observed when similar experiments were
undertaken but this time using ptEBLV-1 (RV9) with the renilla
luciferase reporter, ptEBLV-2 (RV1787) with the ﬁreﬂy luciferase
reporter and sera that covered a range of titres from dogs and rabbits,
previously immunised with commercial RABV vaccines or EBLV-1 and
-2 isolates respectively (0.86; pb0.0001; Pearson's product-moment
correlation; Supplementary Fig. S1).
As there is cross-neutralisation between lyssavirus species LBV and
MOKV we had anticipated greater variation between low VNAb titres
obtained using the single or dual assay due to saturation of theantibodies available with the antigen. While the correlation of ptLBV
and ptMOKV VNAb titres achieved using the single or dual PNAs for
sampleswith a VNAb titre in the single PNAof less than themean (1:48)
was lower than for those above the mean a signiﬁcantly strong
correlation is maintained (r=0.69 [pb0.0001] and 0.92 [pb0.0001]
respectively).With theptEBLV-1 andptEBLV-2 single anddual PNAdata
(Supplementary Fig. S1) sampleswith a VNAb titre, in the single PNA, of
less than the mean (1:4046) had a stronger correlation than for those
with a titre greater than the mean (r=0.86 [pb0.0001] and 0.77
[p=0.006], respectively).
Potent neutralising activity of Ghanaian bat sera against phylogroup 2
lyssavirus
Of the 184 serum samples screened, 56% (n=103) neutralised
ptLBV, 27% (n=48) neutralised ptMOKV and 1% (n=2) neutralised
ptWCBV (Fig. 3A). In Accra 58%, 27% and 1% of the bat sera neutralised
ptLBV, ptMOKV and ptWCBV respectively. In Kumasi and Tanoboase,
ptLBV, ptMOKV and ptWCBVwere neutralised by 59%, 36% and 3% and
51%, 21% and 0% serum samples respectively. Eleven percent of serum
samples neutralised both ptLBV and ptMOKV, 1% of samples
neutralised ptLBV and ptWCBV or ptMOKV and ptWCBV, while only
2 samples neutralised all 3 pseudoviruses. Themean VNAb titre across
all serum samples tested was 1:266 for ptLBV, 1:35 for ptMOKV and
1:7 for ptWCBV (Fig. 3B). There was no statistical difference in VNAb
percentage of neutralising sera or titres among the three sampling
sites (pb0.05; Kruskal–Wallis test).
Four (2%) samples neutralised ptMOKV but not ptLBV or ptWCBV
and 11 (6%) samples had a higher VNAb titre against ptMOKV than
ptLBV. The single H. monstrosus was seropositive against both ptLBV
(1:10240) and ptMOKV (1:1076). The two samples that neutralised
ptWCBV were collected in Accra and Kumasi and had geometric mean
IC100 endpoint reciprocal dilution titres of 1:320 and 1:8. Both also
neutralised ptLBV (1:1280 and 1:226 respectively) and ptMOKV (1:640
and 1:10 respectively) but neither sample neutralised ptCVS-11.
Discussion
Where active surveillance of bats is undertaken, detection of VNAb
and/or viral RNA suggests that the lyssavirus species detected circulate
within the colonies. Understanding virus ecology in bats is particularly
difﬁcult given the behaviour and ecology of the hosts (Freuling et al.,
2009; Vos et al., 2007). Active infections and antibodies toRABVvariants
havebeen reported innumerous bat species inNorth andSouthAmerica
(Belotto et al., 2005) but not in bats on other continents. In the Old
World there are many more species of lyssaviruses, the majority of
whichhavebeen isolated frombats (Botvinkin et al., 2003;Kuzminet al.,
2005, 2010). Our understanding of how viruses persist in different bat
populations is very limited, particularly outside the Americas. The
ecology of EBLV-2, for example, is poorly understood but it appears to
be endemic in designated “rabies free” nations such as the UK (Banyard
et al., 2010, 2009). In Africa there exists greater lyssavirus diversity, and
there is intriguing evidence that LBV, WCBV and SHIBV might be
circulating within different bat species in the same roost (Kuzmin et al.,
2010, 2008b).
The advantages of using pseudotyped viruses as alternatives to
handling live virus have been utilised by many laboratories for over
two decades. They have primarily been used as gene delivery or gene
therapy vectors (Naldini et al., 1996; Zufferey et al., 1997) but more
recently as antigen substitutes in PNAs evaluating antiviral drug
potency (Aljofan et al., 2009; Parry et al., 2009; Su et al., 2008) and
serum VNAb titres (Temperton et al., 2005, 2007; Wright et al., 2008),
as vaccine immunogens (Szecsi et al., 2006, 2009; Yang et al., 2007) or
target antigens in antibody binding assays (Wang et al., 2010). Also,
PNAs have been shown to aid the identiﬁcation of more potent and
broader cross-neutralising MAbs than has been possible using other
Fig. 2. Comparison of serum VNAb titres achieved using the LBV PNA ormFAVN assays. A high correlation (r), sensitivity (Sn) and speciﬁcity (Sp) was observed between the PNA and
mFAVN (A). Samples that were classiﬁed as positive or negative in both assays (Concordant +/−) are shown by circles. Discordant samples classiﬁed as positive in the PNA and
negative in the mFAVN or vice versa are highlighted by + and x, respectively. The dotted line corresponds to the cut-off dilution in each assay. (B) VNAb titres strongly correlate
between single and dual PNAs. ptLBV.NIG56-RV1 (black triangles) and ptMOKV.NIG68-RV4 (grey circles) VNAb titres were determined in separate wells (single) or in the same well
(multiplex). Titres reported are IC100 endpoint reciprocal dilutions r and p values were calculated using Pearson's product-moment correlation.
186 E. Wright et al. / Virology 408 (2010) 183–189neutralisation assays (Corti et al., 2010). The strong correlation (0.83)
and the high sensitivity/speciﬁcity (95/93%) between LBV PNA and
mFAVN VNAb titres observed in this study further validates PNA as a
useful alternative to existing serological assays. Similar PNAs are used
widely in inﬂuenza research to answer important epidemiological and
biological questions with equally accurate results as live virus assays
(Alberini et al., 2009; Garcia et al., 2009).
Wehave further added to theﬂexibility of the lyssavirusPNAscaffold
by including a multiplex platform that could prove valuable for
serosurveillance in bats. By incorporating different luciferase reporter
genes in the viral genome and different envelope glycoproteins on the
viral membrane of separate pseudotype preparations it is now possible
to detect VNAb titres to two viruses in one serum dilution. This holds
great promise for bat serology studieswhere the scales of investigations
are usually limited by the volume of serum collected. With this
multiplex PNA it is possible to use ≤10 μl of sera to obtain VNAb titres
to two viruses, twice as much information than with the standard PNA.
We postulate that it is possible to increase this capacity further by
including pseudotyped viruses encoding ﬂuorescent reporter genes,
such asGFPor RFP, as these signals could be readprior to cell lysis for the
luciferase measurements. It would then theoretically be possible to
undertake serosurveillance for many highly pathogenic viruses that
have been successfully pseudotyped, for example, ﬁloviruses, corona-Fig. 3. Lyssavirus neutralisation by Eidolon helvum serum samples. Percentage of serum sam
MOKV orWCBV. Results for Accra, Kumasi and Tanoboase are denoted by small hatching/circ
horizontal bars represent mean VNAb titres, given as IC100 endpoint reciprocal dilutions. nviruses, henipaviruses and other lyssaviruses, in low containment
laboratories using one serumdilution series and a tiny volume of serum
compared with that required for conventional assays.
In this study, we observed a similar seroprevalence of LBV andMOKV
antibodies in E. helvum as had been reported by other African serologic
studies (Hayman et al., 2008a; Kuzmin et al., 2008a) and a low
seroprevalence of WCBV in Ghanaian E. helvum. The high percentage of
LBV serumpositive bats (56%), approximately 2 years after Hayman et al.
(2008a) ﬁrst detected anti-LBV antibodies in E. helvum in Ghana, provide
support forourhypothesis that LBV is endemicwithin this bat population.
It is currently unknown whether these seropositive animals have ever
been infectious and recovered from a neurological infection or whether
the seropositivity is evidence of peripheral infection that has been
prevented from reaching the nervous system by the host's immune
response. In addition, the difﬁculties of aging adult wild animals and the
problems of undertaking capture-mark-recapture studies in such large
populations of ﬂying wild animals currently limit our knowledge
regarding age-speciﬁc seroprevalence and antibody titre decay rates in
this virus–host system. Until these data are available further conclusions
regarding virus infection dynamicswithin this populationwill be limited,
whether for lyssaviruses or other viral infections against which
antibodies have been detected in E. helvum (Hayman et al., 2008b;
Hayman et al., 2010). However, our results suggest that the risk toples that had neutralising activity (A) and VNAb titres (B) against pseudotyped LBV,
les, large hatching/triangles and horizontal lines/squares in A and B, respectively. In (B)
=184 for ptLBV and ptWCBV and n=178 for ptMOKV.
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occurs in close proximity to them, especially given that they are a food
source across much of Africa (Mickleburgh et al., 2009). A small
proportion (≤11%) of the bat serum neutralised more than one of the
lyssaviruses which is notable. It is probable that some of the ptMOKV
neutralisation observed is due to cross-reaction with LBV VNAb as this
has been reported previously from this species in Kenya and Nigeria
(Dzikwi et al., 2010; Kuzmin et al., 2008a). However, we detected four
serum samples which neutralised ptMOKV but not ptLBV and 11 with a
higher VNAb titre against ptMOKV than ptLBV. There are different
possible explanations for these data. The variable response individuals
show heterologous antigens might explain the variation shown with
these animals (Kuzmin et al., 2008a; Smith et al., 2004). The dynamic
nature of these biological testsmight also affect the VNAb titre, with test-
to-test variation being possible. Also, at the genomic level the domains
containing themajor immuno-dominant epitopesmight appear different
but when folded the antigenic sites might adopt similar conformations.
Alternatively, these datamight show true evidence of previous exposure
to MOKV, although we believe that the variable immune response to
heterologous antigen is the most likely reason for these results,
particularly given the degree of cross-neutralisation in this and previous
studies (Dzikwi et al., 2010; Kuzmin et al., 2008a). It is also interesting to
note one strong (1:320) and one weak (1:8) VNAb titre were recorded
against ptWCBV for different serum samples. Support for cross-
neutralisation as the cause of such observations is provided by the
individual with the 1:320 VNAb titre having a very high titre against
ptLBV (1:1280), and ptMOKV (1:640), perhaps demonstrating that a
strong immune response to LBV can lead to neutralisation of other
lyssaviruses. That this represents a seroprevalence of 1% in our sampled
group of bats, far below what has been recorded for WCBV in other
studies, suggests that even though the same serum samples did not
neutralise ptCVS-11, these results do not constitute convincing evidence
for thepresenceofWCBVcirculating inGhanaianbats. Therefore, analysis
of our results with those of previous studies suggests possible species
speciﬁcity for certain bat lyssaviruses. While LBV RNA and antibodies
havebeendetected in adifferent bat species (Dzikwi et al., 2010;Hayman
et al., 2008a; Kuzmin et al., 2008a), MOKV infection has never been
reported in bats andWCBV has only been isolated inMiniopterus species
(Botvinkin et al., 2003; Kuzmin et al., 2008b). Evidence of LBV andWCBV
infection has been reported within the same cave colony but in different
bat species (Kuzmin et al., 2008a,b). This may suggest a restricted host
range for certain lyssaviruses, possibly due to cellular, behavioural, or
ecological restrictions that may have evolved during the co-evolution of
the host and virus. However,withmore intensive, far reaching virological
studies, MOKV andWCBVmight be isolated from bats or more than one
species respectively. Therefore, seroprevalence studies are needed to
elucidate the true distribution of LBV, MOKV andWCBV and we propose
themultiplexed PNAwe describe will substantially improve surveillance
capabilities. Given our studies also provide evidence of endemic
circulation of LBV within bat populations in urban centres, further
studies are necessary in order to understand both virus dynamics at the
population level and species speciﬁcity at the cellular level.
Conclusion
The results of this study increase our understanding of the natural
history of lyssaviruses, providing the ﬁrst evidence that Lagos bat virus
might be endemic in urban dwelling E. helvum bat populations. Using a
novel multiplexed PNA we also detect neutralisation of MOKV and
WCBV by LBV antibody positive sera. From these observations, coupled
with at least a dozen documented cases of non-RABV lyssavirus spill-
over events into humans with a 100% fatality rate (Belikov et al., 2009;
Johnson et al., 2010) and that many other cases have probably been
unrecorded or misdiagnosed as RABV infections, it is clear that the
extent of the public health threat posed by zoonotic transmission of
highly pathogenic lyssaviruses from bats is still not entirely understood.In particular, understanding lyssavirus dynamics and whether bat
lyssaviruses are restricted in their host species range is necessary in
order to understand the potential risk of cross-species transmission and
virus spill over. Therefore, further studies leading to a greater
understanding of lyssavirus molecular biology and epidemiology are
required to address this knowledge gap, which will ultimately aid the
design of novel antivirals against these emerging viruses.
Methods
Virus isolates, plasmids and pseudotype production
The LBV Nigeria 1956 (LBV.NIG56-RV1) isolate (Boulger and Porter-
ﬁeld, 1958; Shope et al., 1970)was used in themFAVNassays. To produce
infectious pseudotype particles for use in PNAs the glycoprotein (G-)
genes from LBV.NIG56-RV1 (GenBank accession number: HM623779)
and a Nigerian MOKV isolated in 1968 ((Kemp et al., 1972; Shope et al.,
1970); MOKV.NIG68-RV4; GenBank accession number: HM623780)
were ampliﬁed using speciﬁc primers (Supplementary table S1) and
cloned into a pUC-based expression plasmid (pI.18). WCBV G-gene
((Kuzmin et al., 2008c); EF614258) was chemically synthesised (Gene-
script, USA) and then sub-cloned into pI.18. These were then expressed
concurrentlywith theHIV type1gag-pol plasmid (pCMV-Δ8.91) andone
of the following reporter plasmids: pCSGW (GFP), pCSFLW (ﬁreﬂy
luciferase)orpCSRLW(renilla luciferase).Detailed information regarding
plasmids, pseudovirus production and titrationhasbeengivenpreviously
(Wright et al., 2009, 2008) apart from pCSRLW, which comprises the
pCSGW backbone with the renilla luciferase gene subcloned in place of
the GFP gene (Alberini et al., 2009; Demaison et al., 2002). GFP
pseudotype titres were comparable for ptLBV.NIG56-RV1 (2.9×105
infectious units (IFU)/ml) and ptWCBV (7.2×105 IFU/ml) but a log10
lower for ptMOKV.NIG68-RV4 (3.8×104 IFU/ml).
Cell lines
A highly transfectable derivative of the 293 cell line, human
embroyonic kidney 293T clone-17 cells (HEK 293T/17; ATCC CRL-
11268) were used for pseudotype production and maintained in
Dulbecco's Modiﬁed Eagle Medium (DMEM) supplemented with
Glutamax and 15% foetal calf serum (FCS) at 10% CO2. Baby hamster
kidney-21 clone-13 cells (BHK-21; ATCC CCL-10), used for pseudo-
type and mFAVN neutralisation assays, were cultured in DMEM with
10% FCS, 1% penicillin/streptomycin and 5% CO2.
Study area and serum samples
In March 2009, 184 serum samples were collected from three large
E. helvum colonies within Ghana: Accra (urban; n=93), Kumasi
(urban; n=34) and Tanoboase (rural; n=57; Fig. 1A). Ethical
approval for the capture and study of the bats was given by the
Zoological Society of London Ethics Committee (WLE/0467). Bats
were caught using 6- to 18-m mist nets when returning to their
roosting sites. Blood samples were taken from the propatagial vein
while bats were manually restrained (Fig. 1B). Sera were prepared by
centrifugation of blood at 3,000 rpm for 15 min, heat-treated at 56 °C
for 30 min before and storage at −70 °C immediately. Six serum
samples contained insufﬁcient volumes for testing for MOKV VNAb.
Separate rabbit anti-sera raised against the LBV.NIG56-RV1 isolate and
against a Duvenhage virus isolate recovered in a bat from Zimbabwe
(RV131;(Johnson et al., 2002)) were used as positive control sera in the
PNAs.
Neutralisation assays
Standard, single pseudotype neutralisation assays were conducted
as previously described (Wright et al., 2009, 2008). To allow the
188 E. Wright et al. / Virology 408 (2010) 183–189detection of VNAb to two pseudoviruses in one well of a tissue culture
plate using ≤10ul of serum, a multiplex or dual assay was developed.
This assay was undertaken using the same protocol as the single assay
apart from: (1) Two lyssavirus pseudotypes, 100× TCID50 of both,
were added to each well of the assay plate, one contained a ﬁreﬂy
luciferase reporter gene and the other a renilla luciferase reporter
gene, and (2) following the normal 48 h incubation the plates were
assayed using the Dual-Glo® reagent (Promega, UK) instead of the
Bright-Glo® reagent (Promega, UK), as detailed in the manufacturer's
instructions. The Dual-Glo® reagent can differentiate between the
ﬁreﬂy and renilla luciferase signal so a VNAb titre for each lyssavirus
pseudotype could be recorded for each serum sample concurrently.
All neutralisation data reported in this study was undertaken using
LBV, MOKV, WCBV or CVS-11 PNA but to allow comparison of VNAb
titres samples were also tested in a LBV mFAVNs, which were
undertaken as described previously (Hayman et al., 2008a). As with
the widely used FAVN assay, titres reported correspond to 100%
neutralisation of pseudotype or virus input and are reported as IC100
endpoint reciprocal dilutions, Statistical analyses were undertaken
using GraphPad Prism (GraphPad Software, San Diego, CA, USA).
It should be noted that the method for scoring sera as positive or
negative bymFAVNor PNAwas the sameas that used in a previous study
in which no sera cross-neutralised with CVS-11 (Hayman et al., 2008a).
In theabsenceof knownuninfectedE. helvum colonies thesensitivity and
speciﬁcity of this assay cannot be known, however in Hayman et al.
(2008a) a 1:9 dilutionwas a three-fold dilution above the 1:3 dilution at
which there was no virus neutralisation using standard FAVN methods
against rabies (CVS-11; Cliquet et al., 1998), and therefore deemed an
acceptable cut-off. Similarly we observed no neutralisation of ptCVS-11
above a dilution of 1:20 using the PNA and serum samples collected for
the current study (data not shown). Therefore, we considered anymean
neutralising titre above the next dilution in the series, 1:40 for the PNA
and N1:9 for the mFAVN, seropositive.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.virol.2010.09.014.
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